Connective tissue disease merger interstitial lung disease
Conditions
Interventions
Control Group:Cyclophosphamide
Healthy control group:/
Experimental group:Runfei Huayu recipe
Experimental group:Prednisone
Experimental group:Cyclophosphamide
Sponsors
Taizhou Hospital of traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
35 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Meet the diagnostic criteria of traditional Chinese and western medicine for CTD-ILD; 2. 35 years = age =75 years, male or female; 3. This study was approved by the ethics committee of our hospital, and informed consent was obtained from patients with signed informed consent; 4. No fertility requirement.
Exclusion criteria
Exclusion criteria: 1. Patients with pulmonary tuberculosis, chronic obstructive pulmonary disease, emphysema, bronchiectasis, lung tumors, silicosis, pneumoconiosis and other lung diseases; 2. Patients with some serious primary diseases, such as digestive, respiratory, cardiovascular, hematopoietic and nervous system diseases, mental diseases, etc.; 3. Abnormal liver and kidney function, such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST) exceeding 1.5 times the normal value, blood creatinine (Scr) and urea nitrogen (BUN) any higher than the normal value; 4. Allergic constitution and allergic to clinical study medication; 5. Women who are during pregnancy, preparing for pregnancy, or during breastfeeding period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lung function;Lung CT; | — |
Secondary
| Measure | Time frame |
|---|---|
| TCM syndrome integral; | — |
Countries
China
Contacts
Public ContactLing Li
Outcome results
None listed